{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/neuropathic-pain-drug-treatment/prescribing-information/duloxetine/","result":{"pageContext":{"chapter":{"id":"201a6fcc-11c6-5f00-b820-7fa69ee8b95d","slug":"duloxetine","fullItemName":"Duloxetine","depth":2,"htmlHeader":"<!-- begin field 6d8d0292-bab2-44dc-bb99-95405a1dc9b2 --><h2>Duloxetine</h2><!-- end field 6d8d0292-bab2-44dc-bb99-95405a1dc9b2 -->","summary":"","htmlStringContent":"<!-- begin item 2f7d6564-6fb4-47b8-9489-a22131337cdf --><!-- end item 2f7d6564-6fb4-47b8-9489-a22131337cdf -->","topic":{"id":"b1f9c908-6cb6-5afd-a737-0a621c6232d0","topicId":"35e3d915-8243-4418-a7dd-6590d8ca5c85","topicName":"Neuropathic pain - drug treatment","slug":"neuropathic-pain-drug-treatment","lastRevised":"Last revised in December 2020","chapters":[{"id":"0c243e96-3697-5ee3-98c7-9ffecf07f2af","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"94d784c6-0537-5187-a548-a95e6ad2f899","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"855f03f8-54cb-5675-a6b8-aeb8064288d7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f0b9b63a-bd52-51b6-8eda-cb26c9f551a0","slug":"changes","fullItemName":"Changes"},{"id":"2e3e3fff-20af-56ab-b8f8-a9ee4f14f833","slug":"update","fullItemName":"Update"}]},{"id":"80218328-d006-5b34-a01a-0ef4dbeaf7d5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"22989c5e-df85-5aba-bd66-8c44723e59d7","slug":"goals","fullItemName":"Goals"},{"id":"722de221-9258-5985-8a02-c088cf258a12","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"bf3b0c22-2d82-5464-bf76-bc066dae256f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c6576f2f-fd04-5900-a5e1-517233523e2c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"dd2de31a-79d5-5c20-9132-c99c41c12822","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"148cc621-37d8-5264-a358-c380fcfb4223","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"eddf36b3-7bc8-53c9-9c59-fa36b809f229","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"025ef443-81b5-565d-8240-d76615c27e55","slug":"definition","fullItemName":"Definition"},{"id":"3704349e-d3ae-5a8b-ba94-9da5282ed77f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e18339e8-95d0-582f-ad51-0614dae8f855","slug":"complications","fullItemName":"Complications"},{"id":"9b552f08-01aa-583d-900b-9cbdc90fe28d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"21d7485a-b855-5ba4-82bc-ca3154184325","fullItemName":"Management","slug":"management","subChapters":[{"id":"bad22859-57ae-5c1c-a944-c3d9fef6d160","slug":"neuropathic-pain-drug-treatment","fullItemName":"Scenario: Neuropathic pain - drug treatment"}]},{"id":"0d8cb386-e038-5d6f-83af-81664da82cca","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a91a8f28-db46-58e8-9df7-f30be0f00f2b","slug":"amitriptyline","fullItemName":"Amitriptyline"},{"id":"382b9603-7b46-57d1-9b07-fa743886796e","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"498f1249-e619-5b41-b42b-1a914239d269","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"201a6fcc-11c6-5f00-b820-7fa69ee8b95d","slug":"duloxetine","fullItemName":"Duloxetine"},{"id":"56e4231d-ab93-5963-bc8a-989240189179","slug":"capsaicin-cream","fullItemName":"Capsaicin cream"},{"id":"01a263c7-9fe1-5a29-95ec-24e56c0c1bc9","slug":"tramadol","fullItemName":"Tramadol"}]},{"id":"9ed9a9fb-0b52-50ef-8980-c1303531094d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4fd6ab13-09e0-57f4-a265-464eeab8c835","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"3eb7f136-ffd0-5f27-b2d1-21b49247596d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"606fc7bf-da44-5385-95f8-0139b3c57ef7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"9fc3997f-80c3-5333-b5bd-3b3a518bdde6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"74708745-26ce-5fd4-8c02-67ba25b5a355","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4f5855b4-c905-54ca-b02a-820f8fdd4a4a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f09723db-fe39-5bbd-b643-d063fcd61d42","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0d8cb386-e038-5d6f-83af-81664da82cca","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"51b0280f-e40b-5b8b-9e83-46adb40d28bf","slug":"licensed-indication","fullItemName":"Licensed indication","depth":3,"htmlHeader":"<!-- begin field 48f99f09-0617-4716-b4c6-8975e02fc8b7 --><h3>Is duloxetine licensed for neuropathic pain?</h3><!-- end field 48f99f09-0617-4716-b4c6-8975e02fc8b7 -->","summary":"","htmlStringContent":"<!-- begin item 2111b9cf-9741-4ce7-84ca-dceb4543df18 --><!-- begin field d442f8fe-b7bf-45ab-8fef-dbb3710f4f4d --><ul><li>Duloxetine is licensed for the treatment of diabetic peripheral neuropathic pain [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">ABPI, 2020b</a>]. </li><li>However, the National Institute for Health and Care Excellence recommends duloxetine as a first-line treatment option for adults with all neuropathic pain (except trigeminal neuralgia) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">NICE, 2019a</a>]. </li></ul><!-- end field d442f8fe-b7bf-45ab-8fef-dbb3710f4f4d --><!-- end item 2111b9cf-9741-4ce7-84ca-dceb4543df18 -->","subChapters":[]},{"id":"af9d298a-3dc0-5267-b004-a404f21c9fd5","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field de5f3c8a-2e25-4669-b7cb-6ece2227ec35 --><h3>Dose and titration</h3><!-- end field de5f3c8a-2e25-4669-b7cb-6ece2227ec35 -->","summary":"","htmlStringContent":"<!-- begin item f32f25e2-04ff-447c-af76-926a84caf3f5 --><!-- begin field 6922f635-1895-425a-a972-a140f624e3a3 --><ul><li>The initial dose is 60 mg once daily. If necessary, increase the dose up to a maximum of 120 mg a day (in two divided doses). </li><li>Consider trialling duloxetine for up to 8 weeks before deciding it is not effective.<ul><li>Additional response after 8 weeks is unlikely.</li><li>Reassess treatment at least every 3 months.</li></ul></li><li>If duloxetine is not effective or not tolerated, discontinue treatment gradually over a minimum of 1–2 weeks in order to reduce the risk of withdrawal reactions.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">ABPI, 2020b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 6922f635-1895-425a-a972-a140f624e3a3 --><!-- end item f32f25e2-04ff-447c-af76-926a84caf3f5 -->","subChapters":[]},{"id":"f5d584b7-68df-5863-870b-731ab0fad9f7","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field f3cd8194-7790-4b5d-8a32-0a659c69116d --><h3>Pregnancy and breastfeeding</h3><!-- end field f3cd8194-7790-4b5d-8a32-0a659c69116d -->","summary":"","htmlStringContent":"<!-- begin item 06de4376-e71e-48ff-9c58-7689a6c6641d --><!-- begin field 6b707d7d-41fd-447f-8819-7edde2d6ead4 --><p>​​​​​​<strong>Pregnancy</strong></p><ul><li>Duloxetine should only be used in women who are pregnant if the benefits outweigh the risks.</li><li>If taken in late pregnancy, there is a possible risk of neonatal withdrawal symptoms, and persistent pulmonary hypertension in the newborn (PPHN).</li></ul><h4>Breastfeeding</h4><ul><li>Duloxetine is excreted in breastmilk in small amounts, however, there is little available data on use during breastfeeding.<ul><li>The US Drugs and Lactation Database (LactMed) advises that if duloxetine is used, the infant should be monitored for drowsiness, adequate weight gain, and developmental milestones, especially in younger, exclusively breastfed infants and when using combinations of psychotropic drugs.</li></ul></li><li>The manufacturer advises that as the safety has not been established, use during breastfeeding is not recommended.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">Joint Formulary Committee, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">LactMed, 2020</a>] </p><!-- end field 6b707d7d-41fd-447f-8819-7edde2d6ead4 --><!-- end item 06de4376-e71e-48ff-9c58-7689a6c6641d -->","subChapters":[]},{"id":"8f5f6249-245d-52fa-b4d9-5a36cacddc75","slug":"other-prescribing-issues","fullItemName":"Other prescribing issues","depth":3,"htmlHeader":"<!-- begin field 6e65c0bc-0908-4c94-ab90-5ac310edb8a3 --><h3>Other prescribing issues</h3><!-- end field 6e65c0bc-0908-4c94-ab90-5ac310edb8a3 -->","summary":"","htmlStringContent":"<!-- begin item 9e7eeb28-b064-4274-b39e-90b9aec003cc --><!-- begin field 1c30dfad-0d1b-4b25-84e1-43fd4e055db0 --><ul><li>For further information on how to prescribe duloxetine, including contraindications and cautions, adverse effects, drug interactions, and use in pregnancy and breastfeeding, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a>.</li></ul><!-- end field 1c30dfad-0d1b-4b25-84e1-43fd4e055db0 --><!-- end item 9e7eeb28-b064-4274-b39e-90b9aec003cc -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}